|MDACC Study No:||2011-1190 (clinicaltrials.gov NCT No: NCT01489059)|
|Title:||A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with Ipilimumab in Subjects with Unresectable Stage III or Stage IV Melanoma|
|Principal Investigator:||Patrick Hwu|
|Treatment Agent:||Ipilimumab; Recombinant Interleukin-21|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of BMS-982470 that can be combined with ipilimumab and given to patients with
advanced metastatic melanoma.
BMS-982470 is a modified (that is, changed in a laboratory) form of a protein
called interleukin-21 that is normally made by your immune system. This
protein is designed to trigger other cells in your immune system to start
attacking cancer cells.
Ipilimumab is designed to increase the immune system's ability to fight cancer.